Advanced Heart Failure Transplant Cardiology (AHFTC) Fellows

Leila Beach, MD

Dr. Leila Yeh Beach studied chemistry as an undergraduate at Stanford before going on to earn her MD from the UCSF School of Medicine. During this period, she spent a year in Beijing investigating the heparin contamination incident alongside teams from the FDA and Peking University. She subsequently completed her internal medicine residency at UCSF where she conducted research regarding cardiovascular health outcomes disparities along race and ethnic lines. She is now back at Stanford for her cardiology fellowship and hopes to apply her research interest in racial and ethnic disparities to her clinical interest in heart failure and transplant.


Stephanie Hsiao, MD

Dr. Stephanie Hsiao grew up in Taipei, Taiwan.  She attended undergraduate at UC Berkeley and obtained her Master’s degree in Pharmacology at Cambridge University.  She obtained her MD from UCSF.  She completed her Internal Medicine residency and General Cardiology fellowship at the California Pacific Medical Center in San Francisco. She served as both the chief resident and chief cardiology fellow during her training there.  She has a strong interest in medical education and quality improvement.  Her research interests include VA-ECMO indications and outcomes, MCS shock protocol, and advanced heart failure therapies referral patterns.   She plans to pursue a career in medical education and lead quality improvement projects to deliver equitable care for patients needing advanced heart failure therapies.


Daniel Katz, MD

Dr. Daniel H. Katz is from Chicago and received his B.A. and M.D. from Northwestern University. He completed internal medicine training at Massachusetts General Hospital and cardiovascular medicine fellowship at Beth Israel Deaconess Medical Center. At Beth Israel, he spent two years with the Gerszten Lab with support from the cardiovascular training grant.  His research focuses on multi-omic profiling of cardiometabolic disease, specifically heart failure and cardiomyopathy, and has particular experience with proteomics and metabolomics. Dan plans to extend this experience to advanced heart failure patients in an effort to better target therapies and time interventions.